General
Preferred name
IRBESARTAN
Synonyms
SR-47436 D4 ()
BMS-186295 D4 ()
Irbesartan D4 ()
SR-47436 ()
BMS-186295 ()
Irbesartan (Avapro) ()
BMS-186295, SR-47436,APROVEL ()
IRBESARTAN HYDROCHLORIDE ()
[3H]irbesartan ()
Irbesartan component of ibersartan/hydrochlorothiazide zentiva ibersartan ()
Irbesartan component of ibersartan/hydrochlorothiazide ibersartan ()
IRBESARTAN TEVA ()
IRBESARTAN BMS ()
Irbesartan component of coaprovel ()
APROVEL ()
AVAPRO ()
IFIRMASTA ()
Irbesartan zentiva (previously irbesartan winthrop) ()
IRBESARTAN ZENTIVA ()
NSC-758696 ()
Irbesartan component of avalide ()
Irbesartan component of ifirmacombi ()
SR 47436 ()
SABERVEL ()
SARBEVEL ()
Irbesartan component of ibersartan/hydrochlorothiazide teva ibersartan ()
Karvea ()
Irbesartan-d4 ()
IRBESARTAN COMPONENT OF AVALIDE ()
IRBESARTAN COMPONENT OF COAPROVEL ()
IRBESARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE IBERSARTAN ()
IRBESARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA IBERSARTAN ()
IRBESARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA IBERSARTAN ()
IRBESARTAN COMPONENT OF IFIRMACOMBI ()
IRBESARTAN ZENTIVA (PREVIOUSLY IRBESARTAN WINTHROP) ()
Ifirmasta (previously irbesartan krka) ()
P&D ID
PD001208
CAS
138402-11-6
1216883-23-6
Tags
available
drug
Approved by
EMA
FDA
First approval
1997
2008
Drug indication
Atrial fibrillation
Hypertension
Coronavirus Disease 2019 (COVID-19)
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The position of the tritiated hydrogen atom is unspecified by the reference describing this compound and so the radiolabel is not shown in this structure. (GtoPdb)
DESCRIPTION Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1].
PRICE 40
DESCRIPTION Highly potent and selective CB2 inverse agonist (Tocris Bioactive Compound Library)
DESCRIPTION Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
3
Compound Sets
33
AdooQ Bioactive Compound Library
A10477
Cayman Chemical Bioactives
11952
25509
ChEMBL Approved Drugs
CHEMBL1513
CHEMBL6068339
ChEMBL Drugs
CHEMBL1513
CHEMBL6068339
Concise Guide to Pharmacology 2017/18
589
Concise Guide to Pharmacology 2019/20
589
Concise Guide to Pharmacology 2021/22
589
Concise Guide to Pharmacology 2023/24
589
Drug Repurposing Hub
DrugBank
DB01029
DrugBank Approved Drugs
DB01029
DrugCentral
1481
DrugCentral Approved Drugs
1481
DrugMAP
DM5S7IG
DMTP1DC
DrugMAP Approved Drugs
DMTP1DC
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101093
EUbOPEN Chemogenomics Library
EUB0000834
Guide to Pharmacology
589
6908
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1513
Mcule NIBR MoA Box Subset
MCULE-9617953373
MedChem Express Bioactive Compound Library
HY-B0202
NCATS Inxight Approved Drugs
J0E2756Z7N
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Irbesartan(Avapro)
TargetMol Bioactive Compound Library
T1615
The Spectrum Collection
Tocris Bioactive Compound Library
5798
Withdrawn 2.0
EMA22
External IDs
62
Properties
(calculated by RDKit )
Molecular Weight
428.23
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
3
cLogP
4.78
TPSA
87.13
Fraction CSP3
0.4
Chiral centers
0.0
Largest ring
6.0
QED
0.59
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Angiotensin Receptor
Apoptosis
AT1 receptor
AGTR1, JUN, SLC10A1
Pathway
GPCR/G protein
Endocrinology/Hormones
Primary Target
Angiotensin AT1 Receptors
MOA
RAAS inhibitor
Antagonist
Angiotensin AT1 Antagonists
angiotensin receptor antagonist
Member status
member
Disease Area
cardiology, nephrology
Indication
hypertension, diabetic nephropathy
ATC
C09CA04
Therapeutic Class
Antihypertensive Agents
Antiviral Agents
Recommended Cell Concentration
100 nM
Source data